MAPT and Alzheimer disease: These results are in a good agreement with previous findings demonstrating that ACE2 activity was significantly reduced in the brain of AD patients compared with age-matched controls and correlated inversely with levels of Aβ and phosphorylated tau [25], ACE2 activity also showed a tendency to decrease in the serum of AD patients compared with normal controls [24].